Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Tajikistan

Tajikistan

The revenue in the Other Vaccines market of Tajikistan is expected to reach US$2.21m in 2024.
This projection indicates an annual growth rate (CAGR 2024-2029) of 11.51%, leading to a market volume of US$3.81m by 2029.
When compared globally, United States is predicted to generate the highest revenue in this market, amounting to US$24,730.00m in 2024.
Tajikistan is experiencing a growing demand for other vaccines, driven by increased awareness and government initiatives.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

As the world continues to focus on the COVID-19 pandemic, other vaccines are still in demand in Tajikistan.

Customer preferences: The demand for other vaccines in Tajikistan is driven by the need to prevent diseases such as hepatitis, measles, and rubella. Customers prefer to get vaccinated to avoid contracting these diseases, especially since Tajikistan has experienced outbreaks of measles in recent years. Additionally, parents prioritize vaccinating their children to ensure their health and wellbeing.

Trends in the market: The other vaccines market in Tajikistan is expected to grow steadily in the coming years. This growth can be attributed to the government's efforts to improve the country's healthcare system, including the expansion of immunization programs. Furthermore, the increasing awareness of the importance of vaccination among the population is also driving demand for other vaccines.

Local special circumstances: Tajikistan is a developing country with limited resources, which affects the availability and accessibility of vaccines. However, the government has made efforts to improve the situation by partnering with international organizations to provide vaccines to the population. Additionally, the country's geography, with many remote areas, presents challenges in delivering vaccines to all regions.

Underlying macroeconomic factors: The economic situation in Tajikistan remains challenging, with a high poverty rate and limited resources. However, the government has prioritized healthcare spending, including investments in vaccines. The country's strategic location also makes it an important market for vaccine manufacturers looking to expand their presence in Central Asia. Overall, the other vaccines market in Tajikistan is expected to continue growing, driven by both government efforts and increasing awareness among the population.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.